Spin Memory wanted computer memory to keep its speed and lose its power bill. Arm backed the idea. Applied Materials backed it too. Then the long journey from clever physics to paying customers ran out of road.
The Philadelphia spinout is trying to stop acute lung injury before oxidative damage snowballs. Its unusually small peptide has survived mice, pigs and a $25 million financing - but the decisive human test still lies ahead.
A tiny San Diego biotech turned the heart's natural scaffolding into an injectable material, survived the first human test, and then redesigned the delivery. The idea is elegant. Proving it works at scale is the expensive part.